US Dollar vs MXN

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

ENLV Enlivex Therapeutics Ltd

1.45

-0.04 (-2.68%)

Pre Mercado

Última actualización: 08:00:31

Retrasado por 15 minutos

Yet Another Biotech Stock Has Found Success During Tuesday's Session

It appears to be the day for biotechs as yet another company in the space has caught our attention during Tuesday’s session. Earlier in the day, an Illinois-based biotech...

To read the full story on AllPennyStocks.com, click here.

Enlivex Therapeutics (NASDAQ:ENLV)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Haga Click aquí para más Gráficas Enlivex Therapeutics.

Enlivex Therapeutics (NASDAQ:ENLV)
Gráfica de Acción Histórica
De May 2023 a May 2024

Haga Click aquí para más Gráficas Enlivex Therapeutics.

Noticias sobre Enlivex Therapeutics Ltd ENLV

Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
Lunes 29 de Abril 2024 (3 semanas hace) • GlobeNewswire Inc.

Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
Lunes 22 de Abril 2024 (1 mes hace) • GlobeNewswire Inc.

Yet Another Biotech Stock Has Found Success During Tuesday's Session
Martes 16 de Abril 2024 (1 mes hace) • AllPennyStocks.com

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
Martes 16 de Abril 2024 (1 mes hace) • GlobeNewswire Inc.

Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
Jueves 11 de Abril 2024 (1 mes hace) • GlobeNewswire Inc.

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
Jueves 11 de Abril 2024 (1 mes hace) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Miércoles 7 de Febrero 2024 (3 meses hace) • Edgar (US Regulatory)

Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
Miércoles 7 de Febrero 2024 (3 meses hace) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Lunes 22 de Enero 2024 (4 meses hace) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Miércoles 17 de Enero 2024 (4 meses hace) • Edgar (US Regulatory)

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
Miércoles 17 de Enero 2024 (4 meses hace) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Miércoles 20 de Diciembre 2023 (5 meses hace) • Edgar (US Regulatory)

Más de Enlivex Therapeutics Ltd Artículos de Noticias

Vontobel Financial Produ...

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones